Drug-Delivery Microchip Could Replace Daily Injections
In a Small Study, Patients Preferred Microchip Over Daily Injections, and Most Had No Unwanted Side Effects
Feb. 16, 2012 -- An experimental, implanted drug-delivery microchip that releases medication on command from an external wireless control could one day free patients from daily injections and improve treatment compliance.
Results from the first human study of the programmable microchip were reported Thursday in Vancouver at the annual meeting of the American Association for the Advancement of Science -- 15 years after researchers at Massachusetts Institute of Technology (MIT) first came up with the idea for the device.
If future research is promising, the technology could be used to treat a wide range of conditions that require frequent or daily injections, says Robert Farra, the study’s author and chief operating officer of the company developing the drug-delivery device, MicroCHIPS Inc.
“This is the first successful human study of an implantable, wireless microchip that provides 100% treatment compliance and frees patients from the burden of managing their disease on a daily basis,” Farra tells WebMD.
Drug-Delivery Chip Preferred Over Daily Shots
The study, conducted by MicroCHIPS and MIT researchers, originally included eight women in Denmark with severe osteoporosis who had been taking daily injections of the bone-building drug Forteo.
During a 30-minute procedure under local anesthetic, doctors implanted the small devices under the women’s skin below their beltlines. Each device contained 20 doses of the drug sealed in tiny reservoirs on a specially designed microchip.
Immediately after implantation it became evident that the device was not working in one patient, and it was removed.
An analysis of the remaining seven patients confirmed that the microchip delivered the osteoporosis drug in comparable doses to daily injections with no unwanted side effects.
The women reported that they could not feel the devices and expressed a preference for the implanted microchip over daily injections for future treatment.
Farra says his company is now working on a microchip that can deliver a drug for a year or even longer.
If these trials are successful, the devices could be available for clinical use within four years, he says.
Taking Patient Adherence Out of the Equation
MIT professor of engineering Michael J. Cima, PhD, originally developed the idea for a programmable drug-delivery microchip more than a decade ago, along with colleague Robert Langer, ScD.